Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.62 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29222525 | 1.00 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL10834868 | 0.94 | LPAR3 (0.69) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL6284052 | 0.94 | LPAR3 (0.69) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL1123899 | 0.94 | LPAR3 (0.69) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL3814362 | 0.94 | LPAR3 (0.69) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL1123777 | 0.94 | LPAR3 (0.69) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL1261244 | 0.92 | LPAR3 (0.67) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL8747080 | 0.92 | LPAR3 (0.67) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL9436997 | 0.92 | LPAR3 (0.67) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL11369751 | 0.92 | LPAR3 (0.67) | LPAR3LPAR2LPAR1LPAR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008146167-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | INNATE PHARMA S.A. (FR) | 2008-12-04 | — | — | WO | disclosed |